(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 172.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Mesoblast's revenue in 2025 is $17,198,000.On average, 6 Wall Street analysts forecast MESO's revenue for 2026 to be $124,469,129,133, with the lowest MESO revenue forecast at $71,498,967,066, and the highest MESO revenue forecast at $150,524,141,191. On average, 7 Wall Street analysts forecast MESO's revenue for 2027 to be $218,285,604,071, with the lowest MESO revenue forecast at $127,945,520,013, and the highest MESO revenue forecast at $412,354,228,964.
In 2028, MESO is forecast to generate $475,405,412,596 in revenue, with the lowest revenue forecast at $225,325,423,599 and the highest revenue forecast at $840,247,259,578.